Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the <scp>FDA</scp> Adverse Event Reporting System
Our findings provide valuable evidence on common reactions as well as controversial cardiovascular and metabolic abnormalities associated with the real-world use of ETs for breast cancer. Ongoing benefit-risk assessment and close monitoring of cardiac function during treatment, particularly in high-risk women, are warranted to optimize cancer outcomes while minimizing cardiovascular injury.
Authors
- Shaimaa Elshafie (ORCID: https://orcid.org/0000-0001-7279-4418)
- Henry N. Young (ORCID: https://orcid.org/0000-0002-4803-3288)
- Iman Zaghloul
- Lorenzo Villa Zapata (ORCID: https://orcid.org/0000-0002-3821-4595)
- Randall L. Tackett (ORCID: https://orcid.org/0000-0002-0841-5839)
Institutions
- University of Georgia (US)
- Massachusetts College of Pharmacy and Health Sciences (US)
- Egyptian Government (EG)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1002/cam4.70548
- Citations
- 7
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 2.45